NEW YORK, April 11, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Lattice Semiconductor Corporation (NASDAQ:LSCC), W&T Offshore, Inc. (NYSE:WTI), Diplomat Pharmacy, Inc. (NYSE:DPLO), SYNNEX Corporation (NYSE:SNX), Marchex, Inc. (NASDAQ:MCHX), and MEI Pharma, Inc. (NASDAQ:MEIP), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
Complimentary Access: Research Reports
Full copies of recently published reports are available to readers at the links below.
LSCC DOWNLOAD: http://Capital-Review.com/register/?so=LSCC
WTI DOWNLOAD: http://Capital-Review.com/register/?so=WTI
DPLO DOWNLOAD: http://Capital-Review.com/register/?so=DPLO
SNX DOWNLOAD: http://Capital-Review.com/register/?so=SNX
MCHX DOWNLOAD: http://Capital-Review.com/register/?so=MCHX
MEIP DOWNLOAD: http://Capital-Review.com/register/?so=MEIP
(You may have to copy and paste the link into your browser and hit the [ENTER] key)
The new research reports from Capital Review, available for free download at the links above, examine Lattice Semiconductor Corporation (NASDAQ:LSCC), W&T Offshore, Inc. (NYSE:WTI), Diplomat Pharmacy, Inc. (NYSE:DPLO), SYNNEX Corporation (NYSE:SNX), Marchex, Inc. (NASDAQ:MCHX), and MEI Pharma, Inc. (NASDAQ:MEIP) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
-----------------------------------------
Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.
-----------------------------------------
LATTICE SEMICONDUCTOR CORPORATION (LSCC) REPORT OVERVIEW
Lattice Semiconductor's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Lattice Semiconductor reported revenue of $95.98MM vs $95.27MM (up 0.75%) and analysts estimated basic earnings per share -$0.05 vs -$0.06. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Lattice Semiconductor reported revenue of $398.80MM vs $385.96MM (up 3.33%) and analysts estimated basic earnings per share -$0.21 vs -$0.58. Analysts expect earnings to be released on April 30th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.01. The estimated EPS forecast for the next fiscal year is $0.52 and is expected to report on February 11th, 2020.
To read the full Lattice Semiconductor Corporation (LSCC) report, download it here: http://Capital-Review.com/register/?so=LSCC
-----------------------------------------
W&T OFFSHORE, INC. (WTI) REPORT OVERVIEW
W&T Offshore's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, W&T Offshore reported revenue of $143.42MM vs $129.10MM (up 11.09%) and analysts estimated basic earnings per share $0.96 vs $0.17 (up 464.71%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, W&T Offshore reported revenue of $580.71MM vs $487.10MM (up 19.22%) and analysts estimated basic earnings per share $1.72 vs $0.56 (up 207.14%). Analysts expect earnings to be released on May 1st, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.19. The estimated EPS forecast for the next fiscal year is $0.72 and is expected to report on February 26th, 2020.
To read the full W&T Offshore, Inc. (WTI) report, download it here: http://Capital-Review.com/register/?so=WTI
-----------------------------------------
DIPLOMAT PHARMACY, INC. (DPLO) REPORT OVERVIEW
Diplomat Pharmacy's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Diplomat Pharmacy reported revenue of $1,360.63MM vs $1,155.07MM (up 17.80%) and analysts estimated basic earnings per share -$4.01 vs $0.10. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Diplomat Pharmacy reported revenue of $5,492.52MM vs $4,485.23MM (up 22.46%) and analysts estimated basic earnings per share -$4.07 vs $0.23. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.20. The estimated EPS forecast for the next fiscal year is $0.40 and is expected to report on March 20th, 2020.
To read the full Diplomat Pharmacy, Inc. (DPLO) report, download it here: http://Capital-Review.com/register/?so=DPLO
-----------------------------------------
SYNNEX CORPORATION (SNX) REPORT OVERVIEW
SYNNEX's Recent Financial Performance
For the three months ended November 30th, 2018 vs November 30th, 2017, SYNNEX reported revenue of $5,622.20MM vs $5,311.88MM (up 5.84%) and basic earnings per share $2.52 vs $2.28 (up 10.53%). For the twelve months ended November 30th, 2018 vs November 30th, 2017, SYNNEX reported revenue of $20,053.76MM vs $17,045.70MM (up 17.65%) and analysts estimated basic earnings per share $7.23 vs $7.54 (down 4.11%). Analysts expect earnings to be released on June 27th, 2019. The report will be for the fiscal period ending May 31st, 2019. The reported EPS for the same quarter last year was $2.38. The estimated EPS forecast for the next fiscal year is $12.61 and is expected to report on January 9th, 2020.
To read the full SYNNEX Corporation (SNX) report, download it here: http://Capital-Review.com/register/?so=SNX
-----------------------------------------
MARCHEX, INC. (MCHX) REPORT OVERVIEW
Marchex's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, Marchex reported revenue of $23.13MM vs $21.85MM (up 5.88%) and analysts estimated basic earnings per share -$0.01 vs -$0.02. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Marchex reported revenue of $85.25MM vs $90.29MM (down 5.58%) and analysts estimated basic earnings per share -$0.06 vs -$0.15. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.02. The estimated EPS forecast for the next fiscal year is -$0.07 and is expected to report on February 12th, 2020.
To read the full Marchex, Inc. (MCHX) report, download it here: http://Capital-Review.com/register/?so=MCHX
-----------------------------------------
MEI PHARMA, INC. (MEIP) REPORT OVERVIEW
MEI Pharma's Recent Financial Performance
For the three months ended December 31st, 2018 vs December 31st, 2017, MEI Pharma reported revenue of $2.05MM vs $0.36MM (up 472.07%) and analysts estimated basic earnings per share $0.17 vs -$0.16. For the twelve months ended June 30th, 2018 vs June 30th, 2017, MEI Pharma reported revenue of $1.62MM vs $23.25MM (down 93.02%) and analysts estimated basic earnings per share -$0.97 vs $0.07. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.16. The estimated EPS forecast for the next fiscal year is -$0.77 and is expected to report on August 29th, 2019.
To read the full MEI Pharma, Inc. (MEIP) report, download it here: http://Capital-Review.com/register/?so=MEIP
-----------------------------------------
ABOUT CAPITAL REVIEW
Capital Review is a nationally recognized publisher of financial analysis, research reports, and exclusive market reporting. Institutional investors, registered brokers, professional traders, and personal investment advisers rely on Capital Review to quantify public company valuations, discover opportunity across asset classes, stay informed about market-moving events, and read exclusive analysis of important material developments. With 14 offices worldwide, Capital Review staffs and manages certified and registered financial professionals, including Chartered Financial Analyst® (CFA®) designation holders and FINRA® BrokerCheck® certified individuals with current and valid CRD® number designations, to enable continuous coverage of topics relevant to its regular active reader base.
REGISTERED MEMBER STATUS
Capital Review's oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Capital Review's roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Capital Review have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Capital Review's Compliance department by Phone, at +1 (410) 280-7496, or by E-mail at compliance@Capital-Review.com.
LEGAL NOTICES
Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Capital Review, Capital Review members, and/or Capital Review affiliates are not responsible for any gains or losses that result from the opinions expressed. Capital Review makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Capital Review has not been compensated for the publication of this press release by any of the above mentioned companies. Capital Review is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.
Media Contact:
Morena Zambada, Media Department
Office: +1 (410) 280-7496
E-mail: media@Capital-Review.com
© 2019 Capital Review. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Capital-Review.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.